Citi Remains Bullish on Veradermics, Incorporated (MANE)
Key takeaways
- On April 27, Citi lifted the price target on Veradermics, Incorporated (NYSE:MANE) to $120 from $85, reaffirming a Buy rating on the shares.
- While we acknowledge the potential of MANE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
- READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Citi Remains Bullish on Veradermics, Incorporated (MANE) Noor Ul Ain Rehman Mon, May 11, 2026 at 6:12 AM GMT+7 2 min read C MANE Veradermics, Incorporated (NYSE:MANE) is one of the best performing healthcare stocks so far in 2026. On April 27, Citi lifted the price target on Veradermics, Incorporated (NYSE:MANE) to $120 from $85, reaffirming a Buy rating on the shares. The rating update came after the company announced positive topline results from Part A of its Phase 2/3 trial evaluating VDPHL01 in male pattern hair loss. The firm stated that the data “exceeded our base-case bar across all endpoints”, adding that the safety profile was clean. Citi lifted its view of the odds of success to 75%, and now models 2035 risk-adjusted peak sales of $3 billion, up from the previous $2 billion.
Veradermics, Incorporated (NYSE:MANE) announced on April 27 positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating VDPHL01 in over 500 males with mild-to-moderate pattern hair loss. VDPHL01 is a proprietary extended-release oral minoxidil formulation, and Veradermics, Incorporated (NYSE:MANE) believes that the result positions the formulation to potentially become the first FDA-approved oral pill for pattern hair loss in nearly 30 years, as well as a potential best-in-indication treatment option for the 50 million men with pattern hair loss in the United States.
Veradermics, Incorporated (NYSE:MANE) is a late clinical-stage biopharmaceutical company with a focus on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent dermatological and aesthetic conditions.